1. Home
  2. EWBC vs INCY Comparison

EWBC vs INCY Comparison

Compare EWBC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo East West Bancorp Inc.

EWBC

East West Bancorp Inc.

HOLD

Current Price

$110.11

Market Cap

13.9B

Sector

Finance

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$102.46

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EWBC
INCY
Founded
1998
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Commercial Physical & Biological Resarch
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9B
17.0B
IPO Year
1999
1993

Fundamental Metrics

Financial Performance
Metric
EWBC
INCY
Price
$110.11
$102.46
Analyst Decision
Buy
Buy
Analyst Count
12
20
Target Price
$124.00
$90.71
AVG Volume (30 Days)
525.6K
2.0M
Earning Date
01-22-2026
10-28-2025
Dividend Yield
2.18%
N/A
EPS Growth
14.57
3878.02
EPS
9.07
5.90
Revenue
$2,572,339,000.00
$4,813,105,000.00
Revenue This Year
$8.44
$19.59
Revenue Next Year
$7.04
$10.88
P/E Ratio
$12.17
$17.37
Revenue Growth
6.63
18.09
52 Week Low
$68.27
$53.56
52 Week High
$110.80
$109.28

Technical Indicators

Market Signals
Indicator
EWBC
INCY
Relative Strength Index (RSI) 66.17 54.83
Support Level $105.70 $100.55
Resistance Level $108.47 $107.61
Average True Range (ATR) 2.79 2.94
MACD 0.67 -0.98
Stochastic Oscillator 99.23 45.19

Price Performance

Historical Comparison
EWBC
INCY

About EWBC East West Bancorp Inc.

East West Bancorp Inc operates in U.S. and Asia. The Bank provides range of personal and commercial banking services to individuals and businesses. In addition to offering traditional deposit products that include personal and business checking and savings accounts, money market, and time deposits, the Bank also offers foreign exchange, treasury management and wealth management services. The Bank has three operating segments, (1) Consumer and Business Banking, (2) Commercial Banking and (3) Treasury and Other. The company generates the majority of its revenue from the Commercial banking segment.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: